CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 52 enrolled
Drug / intervention
paroxetine +2 moredrug
Likely dose
Paroxetine CR 12.5–25 mg once daily at bedtime or Nortriptyline 25–75 mg once daily at bedtimeAI-extracted
Key inclusion· 2
  • ✓Diagnosis of Parkinson's disease without dementia
  • ✓Clinical depression
Key exclusion· 2
  • ✕Active psychosis
  • ✕Heart block

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00062738
NCT00062738Phase 2Completed
CompareCT.gov

Treatment of Depression in Patients With Parkinson's Disease

Rutgers, The State University of New Jersey·interventional·Posted Jun 13, 2003·Updated Nov 24, 2015

In Brief

A Phase 2 clinical trial evaluating paroxetine, Nortriptyline, and 1 other intervention for Parkinson Disease and Depression. Completed, enrolled 52 participants across 1 site.

Detailed Summary

The goal of this study is to evaluate the effectiveness and safety of two antidepressants--nortriptyline and paroxetine, compared to placebo in patients with Parkinson's disease and depression.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson Disease, Depression
CountriesUnited States
CollaboratorsGlaxoSmithKline

Timeline

Phase 2CompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 13, 2003
Enrollment StartJun 1, 2003
Primary CompletionJan 1, 2009
TodayJul 2, 2026
Enrollment to primary: 5.6 yearsPosted 23.1 years ago

Interventions

paroxetinedrug

Paroxetine CR 12.5 - 25 mg q hs

Nortriptylinedrug

nortriptyline 25 - 75 mg q hs

placeboother

matching placebo